111 related articles for article (PubMed ID: 21504301)
1. Retrospective, observational data collection of the treatment of phenylketonuria in the UK, and associated clinical and health outcomes.
Macdonald A; Nanuwa K; Parkes L; Nathan M; Chauhan D
Curr Med Res Opin; 2011 Jun; 27(6):1211-22. PubMed ID: 21504301
[TBL] [Abstract][Full Text] [Related]
2. Adherence to clinic recommendations among patients with phenylketonuria in the United States.
Jurecki ER; Cederbaum S; Kopesky J; Perry K; Rohr F; Sanchez-Valle A; Viau KS; Sheinin MY; Cohen-Pfeffer JL
Mol Genet Metab; 2017 Mar; 120(3):190-197. PubMed ID: 28162992
[TBL] [Abstract][Full Text] [Related]
3. Blood phenylalanine control in phenylketonuria: a survey of 10 European centres.
Ahring K; Bélanger-Quintana A; Dokoupil K; Gokmen-Ozel H; Lammardo AM; MacDonald A; Motzfeldt K; Nowacka M; Robert M; van Rijn M
Eur J Clin Nutr; 2011 Feb; 65(2):275-8. PubMed ID: 21119696
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of blood phenylalanine concentrations in children with classical phenylketonuria.
Hartnett C; Salvarinova-Zivkovic R; Yap-Todos E; Cheng B; Giezen A; Horvath G; Lillquist Y; Vallance H; Stockler-Ipsiroglu S
Mol Genet Metab; 2013 Apr; 108(4):255-8. PubMed ID: 23465864
[TBL] [Abstract][Full Text] [Related]
5. Therapy compliance in children with phenylketonuria younger than 5 years: A cohort study.
Walkowiak D; Bukowska-Posadzy A; Kałużny Ł; Ołtarzewski M; Staszewski R; Musielak M; Walkowiak J
Adv Clin Exp Med; 2019 Oct; 28(10):1385-1391. PubMed ID: 31469949
[TBL] [Abstract][Full Text] [Related]
6. Relationships between lumbar bone mineral density and biochemical parameters in phenylketonuria patients.
de Groot MJ; Hoeksma M; van Rijn M; Slart RH; van Spronsen FJ
Mol Genet Metab; 2012 Apr; 105(4):566-70. PubMed ID: 22300845
[TBL] [Abstract][Full Text] [Related]
7. Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria.
Trefz FK; Blau N
Pediatrics; 2003 Dec; 112(6 Pt 2):1566-9. PubMed ID: 14654666
[TBL] [Abstract][Full Text] [Related]
8. "MY PKU": increasing self-management in patients with phenylketonuria. A randomized controlled trial.
Ten Hoedt AE; Hollak CE; Boelen CC; van der Herberg-van de Wetering NA; Ter Horst NM; Jonkers CF; Wijburg FA; Bosch AM
Orphanet J Rare Dis; 2011 Jun; 6():48. PubMed ID: 21708003
[TBL] [Abstract][Full Text] [Related]
9. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
Burton BK; Nowacka M; Hennermann JB; Lipson M; Grange DK; Chakrapani A; Trefz F; Dorenbaum A; Imperiale M; Kim SS; Fernhoff PM
Mol Genet Metab; 2011 Aug; 103(4):315-22. PubMed ID: 21646032
[TBL] [Abstract][Full Text] [Related]
10. Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care.
Camfield CS; Joseph M; Hurley T; Campbell K; Sanderson S; Camfield PR
J Pediatr; 2004 Jul; 145(1):53-7. PubMed ID: 15238907
[TBL] [Abstract][Full Text] [Related]
11. Maternal phenylketonuria: experiences from the United Kingdom.
Lee PJ; Lilburn M; Baudin J
Pediatrics; 2003 Dec; 112(6 Pt 2):1553-6. PubMed ID: 14654664
[TBL] [Abstract][Full Text] [Related]
12. The challenges of managing coexistent disorders with phenylketonuria: 30 cases.
MacDonald A; Ahring K; Almeida MF; Belanger-Quintana A; Blau N; Burlina A; Cleary M; Coskum T; Dokoupil K; Evans S; Feillet F; Giżewska M; Gokmen Ozel H; Lotz-Havla AS; Kamieńska E; Maillot F; Lammardo AM; Muntau AC; Puchwein-Schwepcke A; Robert M; Rocha JC; Santra S; Skeath R; Strączek K; Trefz FK; van Dam E; van Rijn M; van Spronsen F; Vijay S
Mol Genet Metab; 2015 Dec; 116(4):242-51. PubMed ID: 26498184
[TBL] [Abstract][Full Text] [Related]
13. Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence.
Enns GM; Koch R; Brumm V; Blakely E; Suter R; Jurecki E
Mol Genet Metab; 2010; 101(2-3):99-109. PubMed ID: 20678948
[TBL] [Abstract][Full Text] [Related]
14. Stability of blood phenylalanine levels and IQ in children with phenylketonuria.
Anastasoaie V; Kurzius L; Forbes P; Waisbren S
Mol Genet Metab; 2008; 95(1-2):17-20. PubMed ID: 18703366
[TBL] [Abstract][Full Text] [Related]
15. Costs and outcomes over 36 years of patients with phenylketonuria who do and do not remain on a phenylalanine-restricted diet.
Guest JF; Bai JJ; Taylor RR; Sladkevicius E; Lee PJ; Lachmann RH
J Intellect Disabil Res; 2013 Jun; 57(6):567-79. PubMed ID: 22563770
[TBL] [Abstract][Full Text] [Related]
16. Outcomes beyond phenylalanine: an international perspective.
Feillet F; MacDonald A; Hartung Perron D; Burton B
Mol Genet Metab; 2010; 99 Suppl 1():S79-85. PubMed ID: 20123476
[TBL] [Abstract][Full Text] [Related]
17. Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study.
Jahja R; Huijbregts SC; de Sonneville LM; van der Meere JJ; Bosch AM; Hollak CE; Rubio-Gozalbo ME; Brouwers MC; Hofstede FC; de Vries MC; Janssen MC; van der Ploeg AT; Langendonk JG; van Spronsen FJ
Mol Genet Metab; 2013; 110 Suppl():S57-61. PubMed ID: 24183792
[TBL] [Abstract][Full Text] [Related]
18. Plasma cholesterol in adults with phenylketonuria.
Williams RA; Hooper AJ; Bell DA; Mamotte CD; Burnett JR
Pathology; 2015 Feb; 47(2):134-7. PubMed ID: 25551302
[TBL] [Abstract][Full Text] [Related]
19. Blood phenylalanine control in adolescents with phenylketonuria.
Walter JH; White FJ
Int J Adolesc Med Health; 2004; 16(1):41-5. PubMed ID: 15148857
[TBL] [Abstract][Full Text] [Related]
20. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU.
Diamond A; Prevor MB; Callender G; Druin DP
Monogr Soc Res Child Dev; 1997; 62(4):i-v, 1-208. PubMed ID: 9421921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
